Obtenez 3 mois à 0,99 $/mois

OFFRE D'UNE DURÉE LIMITÉE
Page de couverture de Diabetes Insights - Breakthroughs and Innovators

Diabetes Insights - Breakthroughs and Innovators

Diabetes Insights - Breakthroughs and Innovators

Auteur(s): EASD - European Association for the Study of Diabetes
Écouter gratuitement

À propos de cet audio

 EASD presents: Diabetes Insights - Breakthroughs and Innovators Join us for expert interviews and discussions on the latest advances in diabetes research. Discover how groundbreaking medicines and cutting-edge technologies are shaping the future of diabetes treatment and management. Get inspired by the stories of distinguished researchers whose discoveries and contributions have transformed our understanding of diabetes. These podcasts were recorded at the EASD Annual Meeting 2024 in Madrid, Spain. You can learn more about the research discussed by watching the scientific presentations in the EASD Media Centre (https://www.easd.org/media-centre/home.html). New episode released every Friday. Science
Épisodes
  • The EASD's First Clinical Guideline: Assessment and Management of Diabetes Distress

    The EASD's First Clinical Guideline: Assessment and Management of Diabetes Distress
    Dec 12 2025
    In this episode, EASD presents its inaugural clinical guideline on diabetes distress. Drawing on two years of multidisciplinary work, the guideline was developed by clinicians, methodologists, psychologists and people with lived experience. Prof. Jane Speight, Prof. Richard Holt and patient-advocate Michelle Law describe what diabetes distress is (the emotional burden tied to daily self-management) and why routine assessment and supportive care must become part of standard practice. The guideline sets out eight good practice statements to help clinicians normalise conversations about emotional wellbeing, plus graded recommendations for managing distress in adults with type 1 and type 2 diabetes. Psychological interventions are endorsed where evidence supports them, and clinic-level actions that clinicians can deliver without referral are highlighted. The panel also discusses evidence gaps, the need for practical tools and training, and how people living with diabetes can drive implementation by asking for these conversations in clinic. Join EASD TV to hear how this guideline aims to transform diabetes care by putting emotional wellbeing alongside clinical outcomes.
    Voir plus Voir moins
    16 min
  • Population Level Screening to Detect Early Stage Type 1 Diabetes

    Population Level Screening to Detect Early Stage Type 1 Diabetes
    Dec 5 2025
    In this episode, leading experts Anette Ziegler (Helmholtz Munich), Chantal Mathieu (KU Leuven & EASD President), and Anastasia Albanese-O’Neill (Breakthrough T1D) join EASD TV to discuss the emerging global consensus on screening for early-stage type 1 diabetes. They explore why population-wide screening is now considered both feasible and essential, how early detection can prevent DKA and enable access to disease-modifying therapies, and what the new guidance means for clinicians, health systems, and policymakers. From optimal screening ages and two-step testing strategies to implementation challenges, cost-effectiveness, and the promise of prevention, this conversation outlines one of the most significant shifts in type 1 diabetes care in decades.
    Voir plus Voir moins
    14 min
  • Results from the SOUL Trial: The Cardiologists' Perspective

    Results from the SOUL Trial: The Cardiologists' Perspective
    Nov 28 2025
    Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes. The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes and cardiovascular care, and what the findings mean for clinical practice, guideline implementation, and patient access. From cross-disciplinary teamwork to the future of evidence-based prescribing, this episode offers a clear look at how the SOUL trial is shaping modern treatment strategies.
    Voir plus Voir moins
    8 min
Pas encore de commentaire